Abstract:Abstract Objective: DNA amplifications of the cMET locus (METamp) are rare (1-6%) in non-small cell lung cancer (NSCLC). The ability to efficiently identify patients with METamp could accelerate development of cMET-targeting therapies by identifying patients for enrollment efficiently. We developed a self-supervised deep learning algorithm (SSDL) to predict METamp status using H&E stained whole slide images (WSI). Methods: Three datasets (CDtrain, CDNGS, CDFISH) consisting of data from 1,436 advanced NSCLC patients (1 slide/pt) were used to develop an SSDL algorithm to predict METamp status. The METamp+ status across datasets was standardized for CDtrain (n=788, METamp+ Prevalence=15%), CDNGS (n=186, 19 positive, 167 negative, Prev=10%) as harboring ≥5 copies of the gene using NGS(Next Generation Sequencing) and for CDFISH (n=462, 36 positive, 426 negative, Prev=8%) as MET CN gain to centromere 7 ratio (CEN) ≥2.5. The datasets were divided into a discovery set (CDtrain) for training and held-out test sets (CDNGS, CDFISH) for validation. To improve robustness of SSDL, we first pre-trained ResNet34 with Simple Contrastive Learning, using >25k WSIs from diverse sources. During the training phase, 4-fold cross validation was applied on CDtrain. The first 3-layers of ResNet34 were frozen while the final layer and an attention-based aggregation system were trained for METamp prediction. The performance was assessed using sensitivity, specificity, AUC, positive predictive value (PPV), and negative predictive value (NPV) on the test sets. Predictions from the model were binarized using two separate thresholds selected from CDtrain, resulting in a High-Sensitivity model (SSDLSens = 90% Sensitivity) and High-Specificity model (SSDLSpec = 90% Specificity). Each model’s potential impact on patient enrollment is presented below. Results: The trained SSDL models achieved an average cross-validation AUC of 0.77±0.04 across folds. The final trained model with the highest cross-validated AUC was chosen for METamp status prediction on the test sets. The selected model maintained predictive performance on CDNGS (AUC=0.82) and CDFISH (AUC=0.75) test sets. The SSDLSpec model had a PPV more than twice the baseline prevalence in both CDNGS (PPV=27%), and CDFISH (PPV=29%), providing a significant enrichment in METamp+ patients. The SSDLSens model correctly classified ~55% of METamp‒ in CDNGS and CDFISH with NPV of ≥97%. These results suggest a potential reduction in genetic screening by 50% while maintaining high sensitivity. Conclusions: The SSDL model robustly predicted METamp status in independent patient cohorts, regardless of METamp definitions (i.e., by NGS or FISH). We demonstrate the ability to classify patients with high sensitivity or specificity, which can help reduce genetic testing or surface potentially eligible patients for trials, respectively. Citation Format: Chaitanya Parmar, Oscar M. Carrasco-Zevallos, Joshua C. Curtin, Darshana Govind, Bing Xia, S. Martin Shreeve, Songbai Wang, Timothy Jatkoe, Patricia Raciti, Levon Demirdjian, Joel Greshock, Kristopher Standish, Stephen S.F. Yip. Prediction of MET amplification from H&E images in non small cell lung cancer using self-supervised deep learning and its role in clinical trial enrollment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6554.

Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trial

Screen Them All: High-Throughput Pan-Cancer Genetic and Phenotypic Biomarker Screening from H&E Whole Slide Images

Deep Learning and Digital Pathology Power Precision Treatment of Triple-Negative Breast Cancer

Machine learning enabled prediction of digital biomarkers from whole slide histopathology images

Developing a low-cost, open-source, locally manufactured workstation and computational pipeline for automated histopathology evaluation using deep learning

Abstract IA020: AI-powered tool for rapid & reliable bladder cancer screening and surveillance: multicenter validation efforts

Deep Learning Derived Histopathology Image Score for Increasing Phase 3 Clinical Trial Probability of Success

Abstract 6087: Cytomics-on-chip and AI-driven predictive analysis platform for early detection of epithelial cancers

Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer

Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms

Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies

Development and Validation of a Deep Learning Algorithm for Improving Gleason Scoring of Prostate Cancer

Enabling large-scale screening of Barrett’s esophagus using weakly supervised deep learning in histopathology

The CONFIDENT-P trial: Clinical implementation of artificial intelligence assistance in prostate cancer pathology.

Abstract 6554: Prediction of MET amplification from H&E images in non small cell lung cancer using self-supervised deep learning and its role in clinical trial enrollment

Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma

Comparison of whole slide image–based deep learning algorithms and genomic classifiers for assessing the risk of prostate cancer metastasis in surgically treated patients.

Microfluidics-based patient-derived disease detection tool for deep learning-assisted precision medicine

Multi-modal AI for comprehensive breast cancer prognostication

Novel Clinical-Grade Prostate Cancer Detection and Grading Model: Development and Prospective Validation Using Real World Data, with Performance Assessment on IHC Requested Cases

Abstract B082: Early risk stratification of ER+/HER2– breast cancer patients using digital pathology and multi-task, weakly-supervised deep learning